Advancing Innovative Technology into Safe and Effective Medicines

MAY 02, 2017
Amy Jacob



Larry Altstiel, MD, PhD, EVP, Chief Medical Officer, vTv Therapeutics also discussed their team’s programs in type 2 diabetes surrounding an activator of an enzyme called glucokinase and a glucagon-like receptor agonist. “GLP-1s right now are all injectables, and they all have side effects of nausea and vomiting. In our particular case, ours is an oral molecule, and it also doesn’t seem to have the gastrointestinal side effects.”


Copyright© MD Magazine 2006-2017 Intellisphere, LLC. All Rights Reserved.